Avacta is supporting global efforts in combating the COVID-19 pandemic by using its Affimer®  platform to develop diagnostics for COVID-19 antigen testing.

Avacta has generated a large number of Affimer binders to the SARS-COV-2 virus spike protein including Affimer pairs for sandwich assays and Affimer inhibitors of the spike-ACE2 interaction.

Avacta is developing a number of SARS-COV-2 tests:

  • A rapid point-of-care test intended for screening of large populations to diagnose the COVID-19 coronavirus infection.

  • A high throughput laboratory test for the infection, to run on the installed base of mass spectrometers in hospitals and laboratories.

  • An ELISA laboratory test to support global research efforts into the coronavirus that causes COVID-19.

Avacta’s COVID-19 programmes are rapidly evolving. Please see the further information below or contact us via the web form.


Videos / media


Get in touch

Contact us using the form below. Alternatively our email address is:

  • This field is for validation purposes and should be left unchanged.